Measuring the Effects of Psychotropic Medication on Challenging Behavior
Jennifer Zarcone (May Institute)
Date: September 23, 2021
Time: 4:00 PM Eastern
Abstract: In this presentation, a review will be provided of the current medication used for individuals with autism and other developmental disabilities. In addition, I will describe the most commonly used behavioral measures, including rating scales, direct observation, and functional analysis measures and how they can be used within the context of medication evaluations. Recent research on other supplements used with individuals with autism and IDD will also be briefly described (e.g., cannabidiol or CBD). Finally, I will discuss how to collaborate effectively with schools, families, and interdisciplinary teams.
Target Audience: BCBAs, parents, school staff, undergraduate and graduate students
Learning Objectives: are treated with medications and possible side effects associated with medications (both behavioral and physiological effects); (2) utilize methods for effectively measuring medication effects with their clients or students in the community; (3) discuss recent research with recent over the counter supplements (e.g., cannabidiol) and how they may have psychotropic properties; (4) use provided information to effectively collaborate with interdisciplinary teams, families, and community services.
1 BACB CEU available.
Biography: Jennifer Zarcone is the Senior Vice President for Adult Clinical Services and Training at May Institute. Dr. Zarcone provides consultation and clinical support to staff around severe problem behavior, staff and parent training, and medication monitoring.
Dr. Zarcone obtained her doctoral degree from the Experimental Analysis of Behavior program at the University of Florida, Department of Psychology, in 1993. She is a Board Certified Behavior Analyst and a licensed psychologist.
Dr. Zarcone has served as a co-investigator on several multi-center clinical trials in autism research at the University of Rochester Medical Center, and on self-injury at the Kennedy Krieger Institute. She is interested in further development of research in the effects of pharmacological and behavioral interventions in the treatment of severe behavior disorders as well as repetitive behavior disorders in individuals with autism.
Dr. Zarcone has served in leadership positions for the Association of Behavior Analysis (ABAI) on the ABAI Practice Board, and she is a current member of the Science Board. She was the conference coordinator for the annual Autism Conference and a Fellow of ABAI. She served as an associate editor for the Journal of Applied Behavior Analysis, and is currently an associate editor for the Journal of Intellectual Disabilities Research, and the American Journal of Developmental Disabilities. She is serving as Guest Editor for the Behavior Analysis in Practice special issue on Diversity and Inclusion. In addition, Dr. Zarcone is currently on the advisory boards for the Women in Behavior Analysis Conference and the Gatlinburg Conference for Research in Developmental Disabilities.